Continuous electrodermal activity as a potential novel neurophysiological biomarker of prognosis after XXXX - A pilot study.

@entity1 @entity26186 @entity772 @entity1167 @entity2332
AIMS: Neurological outcome prognosis remains challenging in @entity1 undergoing @entity2332 ( @entity2332 ) after cardiac resuscitation. Technological advances allow for a novel wrist-worn device to continuously record electrodermal activity (EDA), a measure of pure sympathetic activity. METHODS: A prospective cohort study was performed to determine the yield of continuous EDA in @entity1 treated with @entity2332 for @entity772 after @entity1167 during @entity2332 and normothermia. Association between EDA parameters (event-related and nonspecific electrodermal responses (ER- @entity26186 , NS- @entity26186 )) and outcome measures (cerebral performance category [CPC]) (Full Outline in UnResponsivenss (FOUR) score) were assessed. RESULTS: Eighteen @entity1 were enrolled. Total number of @entity26186 (66.4 vs 12.0/24h, p=0.02), ER- @entity26186 (39.5 vs 11.2/24h, p=0.009), median amplitude change of all @entity26186 (0.08 vs 0.03 SI, p=0.03) and ER- @entity26186 (0.14 vs 0.05 SI, p=0.025) were higher in @entity1 with favorable (CPC 1-2) versus poor outcome (CPC 3-5) during @entity2332 . Greater differences in EDA parameters were observed during @entity2332 than normothermia. The FOUR score was correlated to the number of all @entity26186 and median amplitudes. CONCLUSIONS: Continuous EDA potentially opens a new avenue for autonomic function monitoring in neurocritically ill @entity1 . It is feasible in the ICU setting, even during hypothermic states. As a measure of a complete neurophysiological circuit, it may be a novel neurophysiologic biomarker of outcome after cardiac resuscitation.
